The global in vitro diagnostics (IVD) market is poised for significant growth, expanding from an estimated $108 billion in 2024 to $190 billion by 2035, at a compound annual growth rate (CAGR) of 5.2% during this period. This growth is driven by several key factors including the rising prevalence of chronic and infectious diseases, an aging global population, and increasing healthcare expenditure worldwide[3].
Market Growth Projections and Drivers
The IVD market’s expansion is largely fueled by the increasing demand for accurate and rapid diagnostic solutions that enable early disease detection and personalized medicine. The COVID-19 pandemic notably accelerated the adoption of IVD technologies, highlighting their critical role in managing infectious diseases. Additionally, the growing geriatric population, lifestyle changes leading to chronic diseases, and the shift towards non-invasive and point-of-care (POC) testing contribute to market growth. Continuous launches of advanced diagnostic assays and integration of technologies such as molecular diagnostics and immunoassays further support this trend[3].
Personalized healthcare is another major driver, with IVD tests providing genetic and molecular insights that allow for tailored treatment approaches, improving treatment efficacy and patient outcomes. The increasing use of POC testing devices, which offer rapid results and greater accessibility, is expected to grow at a higher CAGR compared to traditional laboratory testing, despite laboratory testing currently holding the largest market share (85%)[3].
Market Segmentation
The IVD market is segmented by test type, type of offering, technology, therapeutic area, end users, and geography:
- Test Type: Laboratory testing dominates with 85% market share, but point-of-care testing is growing faster due to convenience and rapid results.
- Type of Offering: Reagents lead with 75% market share, driven by frequent replenishment needs, followed by instruments and services.
- Technology: Immunoassay holds the largest share at 34%, followed by clinical chemistry, hematology, molecular diagnostics, and others.
- Therapeutic Areas: Infectious diseases represent the largest segment, accounting for 41% of the market share, followed by chronic conditions such as autoimmune diseases, cardiovascular disorders, diabetes, renal and oncological disorders.
- End Users: Hospitals hold the largest share (48%) and are expected to maintain dominance, while laboratories are growing at the fastest rate (5.5% CAGR).
- Geographical Regions: North America leads with 39% market share, driven by the US, followed by Europe and Asia. The Asia Pacific region is expected to grow at the highest CAGR of 5.5%, with countries like India and China showing significant growth potential[3].
Key Market Trends and Developments
IVD companies are expanding through both organic growth and acquisitions. For example, Roche invested $295 million in LumiraDx’s point-of-care technology in early 2024, and Bruker acquired ELITechGroup for $942 million. These moves reflect the strategic importance of POC diagnostics and instrument offerings in the market[3].
Recent product launches in 2024 include:
- Exact Sciences’ FDA-approved second-generation Cologuard Plus test for colorectal cancer screening.
- Abbott Molecular’s emergency use authorization for the Alinity m MPXV assay for mpox diagnosis.
- Illumina’s FDA-approved TruSight Oncology Comprehensive test as a companion diagnostic.
- Cepheid’s point-of-care RNA test for hepatitis C virus diagnosis using fingerstick blood samples[3].
Challenges and Opportunities
While the IVD market benefits from technological advances and growing demand, it faces challenges such as regulatory requirements, the need for continuous innovation, and reimbursement issues. However, the increasing focus on personalized medicine, non-invasive testing, and rapid diagnostics presents substantial opportunities for market players.
URL: https://www.rootsanalysis.com/reports/in-vitro-diagnostics-market.html
Key Players
Prominent companies profiled in the market include Abbott Laboratories, Agilent, Becton Dickinson, bioMérieux, Bio-Rad, Danaher Corporation, DiaSorin, Exact Sciences, Fujifilm, Gold Standard Diagnostics, Grifols, Hologic, Illumina, LabCorp, Qiagen, Quest Diagnostics, Quidel, Ortho, Roche, Siemens Healthineers, Sysmex, Thermo Fisher Scientific, and Werfen. These companies are actively involved in developing and commercializing a wide range of IVD solutions across technologies and therapeutic areas[3].
---
This comprehensive analysis underscores the critical role of in vitro diagnostics in modern healthcare, highlighting robust market growth driven by epidemiological trends, technological innovation, and expanding applications in disease diagnosis and management worldwide.
Thank you for reading Roots Analysis report. Kindly get in touch with Roots’ team to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
About Roots Analysis
Roots Analysis is a global leader in market research, competitive intelligence and consulting services across industries. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, and venture and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/
